Posts by Dawn Dufield, Ph.D.
Dawn R. Dufield, PhD is the Scientific Officer for Mass Spectrometry at KCAS Bio, where she has worked since 2018. Previously, she spent over 20 years at Pfizer specializing in quantitative large- and small-molecule LC-MS/MS. She was an early pioneer in combining immunoaffinity with LC-MS/MS for enhanced selectivity, now known as Hybrid LCMS, and co-authored a key white paper on validation of LCMS bioanalytical methods for protein biotherapeutics. Dawn has over 15 years of experience in ADC bioanalysis and recent focus on oligonucleotides/ARCs, with numerous publications and active involvement in WRIB, AAPS, and ASMS.
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In…
Posters & Papers
This presentation, given at the 2025 AAPS PharmSci Conference by Dawn Dufield, PhD, Scientific Officer of Mass Spectrometry at KCAS Bio, reviews Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. If you have any questions about these services or any…
Blogs
Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. It typically requires only one antibody, in contrast to conventional ligand-binding assays (LBAs), which usually need two. This approach leverages the combined selectivity of affinity extraction and the analytical power of tandem…
June 20
- June 21
The age of therapeutic conjugation is upon us! Bioanalysis for support of next generation Antibody Drug Conjugates (ADCs) and Antibody siRNA Conjugates (ARCs) have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines and potentially many other diseases. Recently, we…
Blogs
The age of therapeutic conjugation is upon us! Bioanalysis for support of next-generation Antibody Drug Conjugates (ADCs) and Antibody siRNA Conjugates (ARCs) have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines, and potentially many other diseases. Recently, we have…
Blogs
Those of you attending the 18th annual WRIB meeting in San Antonio, TX are invited to attend a poster presentation being given by members of the KCAS Bio team: Jack Rogers, Jessie Allen, Yoka Thomas, and Cheikh Kane. This project developed and characterized a novel algorithm for automated…
Blogs
Dawn Dufield, PhD is the Scientific Officer for Mass Spectrometry and has been with KCAS Bio since 2018. Before joining KCAS Bio, she worked in the quantitative large and small molecule LC-MS/MS field for Pfizer for over 20 years. Dawn has been a pioneer in the Hybrid LCMS field…
Videos
Dawn Dufield, Ph.D. and Dominic Warrino, Ph.D. discuss their approach to ligand binding assays (LBAs) and hybrid mass spectrometry (Hybrid LC-MS/MS) in this 11-part video series. What Makes a Good CRO for Bioanalysis? Are there any specific technologies that are more useful to have together? What is a…
Blogs
In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront…
Blogs
If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the…
Blogs
Anyone who has been following KCAS for any amount of time has likely heard us discuss the advantages of Hybrid LC-MS/MS for the bioanalysis of large molecules. As pioneers in the technology for many years, KCAS has become a strong proponent of working with our customers to demonstrate the…
News
Dawn Dufield, PhD, Senior Director of Biopharmaceutical LC-MS/MS Services at KCAS Bio, has been invited to lead a workshop discussion session on Lipidomics at an upcoming Gordon Research Conference from August 7-12 in Newry, ME. The event will be a week long conference highlighting recent developments in standardization,…